tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Cocrystal Pharma (COCP) and iTeos Therapeutics (ITOS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cocrystal Pharma (COCPResearch Report) and iTeos Therapeutics (ITOSResearch Report) with bullish sentiments.

Cocrystal Pharma (COCP)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Cocrystal Pharma today and set a price target of $4.00. The company’s shares closed last Wednesday at $0.58, close to its 52-week low of $0.45.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -28.9% and a 22.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Vallon Pharmaceuticals, and Oramed Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cocrystal Pharma with a $4.50 average price target.

See today’s best-performing stocks on TipRanks >>

iTeos Therapeutics (ITOS)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on iTeos Therapeutics today and set a price target of $54.00. The company’s shares closed last Wednesday at $31.92.

According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 8.9% and a 40.3% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals, Corcept Therapeutics, and Bicycle Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for iTeos Therapeutics with a $54.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on COCP:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More